Intraoperative changes in visual signals can predict postoperative vision loss in patients undergoing surgery for recurrent craniopharyngiomas. The researchers report that a one-third drop in a key signal serves as an early warning, enabling timely surgical adjustments. This study is among the first to define a tailored threshold for these high-risk, technically challenging tumors, offering a practical step toward safer, more precise neurosurgical care.

An early warning system for sepsis, one of the deadliest infections for hospital patients, has been approved for use by the FDA, one of the first AI-based medical tools to get clearance.

The tool, developed by Johns Hopkins University researchers and now commercialized by Bayesian Health, detects sepsis hours faster than doctors and has reduced deaths by nearly 20%.

A team of Xiyuan Hospital researchers reveal circadian disruption (CD) as a key driver of cardiovascular disease (CVD) multi-organ comorbidities. Caused by sleep/eating irregularities and shift work, CD disturbs SCN-controlled peripheral rhythms, triggering damage via autonomic/metabolic imbalance and gut dysbiosis, with bidirectional harm between CD and end-organ damage. CD has distinct pathological effects on cardio-cerebral, cardio-hepatic and cardio-renal comorbidities. Chronotherapies and clock-targeted drugs show promise. The study advocates personalized chronomedicine and temporal-dimension integration for network-based CVD management.

The HGP2 Rare Disease Alliance of the Asia-Pacific Region (HGP2 RaDiAnce–APAC) was officially launched in Kuala Lumpur on May 10.

YBhg. Datuk Dr. Nor Fariza Binti Ngah, Deputy Director-General of Health (Research and Technical Support) at the Ministry of Health of Malaysia, and Hou Yong, General Manager of BGI Genomics, joined leading experts to discuss urgent priorities in rare disease diagnosis, genomics, and public health response.

An international research group recently demonstrated that the antibody NG101 promotes the regeneration of damaged spinal cord tissue. Now, under the leadership of scientists at the University of Zurich and Balgrist University Hospital, the group has revealed for the first time how the therapy actually works. With a boost from this novel antibody, new nerve fibers form functional connections once again, allowing patients to become more independent.